MapLight Therapeutics Inc. has entered into a strategic collaboration with SandboxAQ to discover and develop novel therapies targeting a G protein-coupled receptor $(GPCR)$ for central nervous system $(CNS)$ disorders. Under the agreement, SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments. The partnership will combine MapLight's CNS expertise with SandboxAQ's advanced AI and molecular simulation technologies to accelerate the discovery and optimization of potential first-in-class drug candidates. MapLight will have exclusive rights to clinical development and commercialization of compounds resulting from the collaboration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maplight Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9602734-en) on December 16, 2025, and is solely responsible for the information contained therein.